exhibit 10. 6 * portions of this exhibit have been excluded because it both ( i ) is not material and ( ii ) would be competitively harmful if publicly disclosed. framework assignment agreement between herlev hospital and io biotech aps exhibit 10. 6 * portions of this exhibit have been excluded because it both ( i ) is not material and ( ii ) would be competitively harmful if publicly disclosed. framework assignment agreement between herlev hospital and io biotech aps on _ _ _ _ _ _ _ _ _ _ _ _ _ _ 2016, the following parties herlev hospital [ * * * ] ( hereinafter referred to as “ hospital ” ) and io biotech aps [ * * * ] ( hereinafter referred to as the “ company ” ) have entered into a framework assignment agreement regarding the potential assignment from the hospital to the company of intellectual property rights and title in and to certain inventions which may be made by the hospital or any of its employees on the terms and conditions set out in this framework assignment agreement. recitals ( a ) whereas the hospital is a hospital owned and operated by the capital region of denmark ( in danish : hovedstadsregionen ) performing research and providing medical treatment of patients within various medical fields ; ( b ) whereas the hospital inter alia employs researchers, scientists, doctors and other personnel within the medical field who, during and related to their employment at the hospital, may make inventions within their field of expertise ; ( c ) whereas the hospital is entitled, but not obligated, to acquire ownership of such inventions pursuant to the danish act on inventions at public research institutions ; ( d ) whereas the company is a limited liability company incorporated under danish law performing research and experimental development within the field of therapies aiming at activating or boosting t cells that react towards regulatory immune cells for the treatment and prevention of cancer, and / or related activities as per board discretion ; ( e ) whereas the parties have already entered into an option assignment agreement dated 2 january 2015 regarding the grant by the hospital to the company of an option to acquire certain intellectual property rights in and to an invention referred to as indoleamine 2, 3 - dioxygenase based immunotherapy which option the company subsequently has exercised ; ( f ) whereas the company has expressed the desire to acquire similar inventions in order to perform research and development within the field of therapies aiming at activating or boosting t cells